Patients

February is Heart Health Month – Million Hearts Infographic

Working together to prevent one million heart attacks and strokes. 1 of every 3 deaths is caused by heart disease and stroke. Health care costs for heart attack and stroke: $312.6 billion. Leading cause of preventable death in people 40–65 years of age. 2 million plus heart attacks and strokes each year. To prevent 1 million heart attacks and strokes, health care professionals and public health workers should do what we know works: Focus on the ABCS: Aspirin when appropriate; Blood pressure control; Cholesterol management; Smoking cessation. Use health IT: Use electronic health records and other health IT to identify patients who need support to improve their ABCS and then track their progress over time. Use team-based care: Use clinical innovations, including: Use everyone who interacts with patients to the top of their skills and license; Self-measured blood pressure monitoring with clinical support; Reward and recognize excellence in the ABCS. By doing what we know works, health care professionals, health care systems, and public health organizations can help prevent 1,000,000 heart attacks and strokes and meet these goals by 2017: 47 percent to 70 percent increase in aspirin use for secondary prevention; 46 percent to 70 percent increase in blood pressure control; 33 percent to 70 percent increase in cholesterol management; 23 percent to 70 percent increase in help for those who want to quit smoking; 20 percent reduction in sodium consumption; 50 percent reduction in trans-fat consumption. For more information on effectiveness of team-based care, visit: www.thecommunityguide.org/cvd/teambasedcare.html, www.cdc.gov/media/dpk/2013/dpk_13_in_2013.html, www.millionhearts.hhs.gov. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention.

J. Lewis Research, Inc.

J. Lewis Research, Inc.

We are a unique research company in Salt Lake City with over 25 years of experience conducting clinical trials for the pharmaceutical industry, specializing in Phase II, III and IV clinical trials.